Sana Biotechnology CEO Steve Harr shares the company鈥檚 progress in overcoming allogeneic rejection and an update on Sana鈥檚 pipeline heading into 2024. More from Flagship @ JPM2024 here.
Related Companies
- Sana Biotechnology Founded: 2018
More from:
Human Health
What If We Could See Disease Coming and Stop It?
Amanda Kay on a New Approach to Biopharma Partnerships
Pioneering Partnerships: Advancing a Portfolio of Novel Medicines and Vaccines with GSK
Pioneering Partnerships: Accelerating our Collaboration with Pfizer
Unlocking Therapeutic Breakthroughs with the Power of Platform Technologies
